Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients ...
Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, ...
Building a third-line treatment framework starts with molecular profile and available targeted options, but ultimately rests ...
Inebilizumab cut MG exacerbations and rescue therapy use in MINT, and a post hoc analysis found similar responses regardless ...
FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
Most eligible patients stand to benefit from twice-yearly dosing, though candidate selection still matters, and clinical trial data reveal no new safety signals relative to more frequently dosed ...
With multiple oral JAK inhibitors approaching approval, sequencing decisions and adverse-event management are becoming urgent clinical questions. Dr. Desai and Dr. Hamzavi outline how they select ...
Lead VERIFY trial investigator Andrew Kuykendall, MD, explains how rusfertide could replace phlebotomy and ease fatigue in ...
Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...